Detalles de la búsqueda
1.
Long-term outcomes with emicizumab prophylaxis for hemophilia A with or without FVIII inhibitors from the HAVEN 1-4 studies.
Blood
; 137(16): 2231-2242, 2021 04 22.
Artículo
en Inglés
| MEDLINE | ID: mdl-33512413
2.
Effect of emicizumab prophylaxis on bone and joint health markers in people with haemophilia A without factor VIII inhibitors in the HAVEN 3 study.
Haemophilia
; 28(6): 1033-1043, 2022 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-35905294
3.
Emicizumab Prophylaxis in Patients Who Have Hemophilia A without Inhibitors.
N Engl J Med
; 379(9): 811-822, 2018 08 30.
Artículo
en Inglés
| MEDLINE | ID: mdl-30157389
4.
Development and testing of the Satisfaction Questionnaire with Intravenous or Subcutaneous Hemophilia Injection and results from the Phase 3 HAVEN 3 study of emicizumab prophylaxis in persons with haemophilia A without FVIII inhibitors.
Haemophilia
; 27(2): 221-228, 2021 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-33506955
5.
Low immunogenicity of emicizumab in persons with haemophilia A.
Haemophilia
; 27(6): 984-992, 2021 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-34480814
6.
The effect of emicizumab prophylaxis on long-term, self-reported physical health in persons with haemophilia A without factor VIII inhibitors in the HAVEN 3 and HAVEN 4 studies.
Haemophilia
; 27(5): 854-865, 2021 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-34171159
7.
Determining meaningful health-related quality-of-life improvement in persons with haemophilia A using the Haemophilia Quality of Life Questionnaire for Adults (Haem-A-QoL).
Haemophilia
; 26(6): 1019-1030, 2020 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-33084166
8.
Crovalimab for treatment of patients with paroxysmal nocturnal haemoglobinuria and complement C5 polymorphism: Subanalysis of the phase 1/2 COMPOSER study.
Br J Haematol
; 198(3): e46-e50, 2022 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-35608260
9.
Patient preference for emicizumab versus prior factor therapy in people with haemophilia A: Results from the HAVEN 3 and HAVEN 4 studies.
Haemophilia
; 27(6): e772-e775, 2021 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-34623725
10.
Patterns of failure after involved field radiation therapy for pediatric and young adult Hodgkin lymphoma.
Pediatr Blood Cancer
; 61(7): 1210-4, 2014 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-24523203
11.
C/EBPα and C/EBPα oncoproteins regulate nfkb1 and displace histone deacetylases from NF-κB p50 homodimers to induce NF-κB target genes.
Blood
; 117(15): 4085-94, 2011 Apr 14.
Artículo
en Inglés
| MEDLINE | ID: mdl-21346255
12.
Application of systems biology to identify pharmacological mechanisms of thrombotic microangiopathy evoked by combined activated prothrombin complex concentrate and emicizumab.
Sci Rep
; 13(1): 10078, 2023 06 21.
Artículo
en Inglés
| MEDLINE | ID: mdl-37344529
13.
Mitigating Drug-Target-Drug Complexes in Patients With Paroxysmal Nocturnal Hemoglobinuria Who Switch C5 Inhibitors.
Clin Pharmacol Ther
; 113(4): 904-915, 2023 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-36660902
14.
Surgical outcomes in people with hemophilia A taking emicizumab prophylaxis: experience from the HAVEN 1-4 studies.
Blood Adv
; 6(24): 6140-6150, 2022 12 27.
Artículo
en Inglés
| MEDLINE | ID: mdl-35939785
15.
Cyclophosphamide for rapid-onset obesity, hypothalamic dysfunction, hypoventilation, and autonomic dysregulation syndrome.
J Pediatr
; 158(2): 337-9, 2011 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-20727534
16.
NF-kappa B p50 regulates C/EBP alpha expression and inflammatory cytokine-induced neutrophil production.
J Immunol
; 182(9): 5757-62, 2009 May 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-19380823
17.
Effects and Interferences of Emicizumab, a Humanised Bispecific Antibody Mimicking Activated Factor VIII Cofactor Function, on Coagulation Assays.
Thromb Haemost
; 119(7): 1084-1093, 2019 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-31064025
18.
Efficacy of emicizumab prophylaxis versus factor VIII prophylaxis for treatment of hemophilia A without inhibitors: network meta-analysis and sub-group analyses of the intra-patient comparison of the HAVEN 3 trial.
Curr Med Res Opin
; 35(12): 2079-2087, 2019 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-31355677
19.
CCAAT/enhancer binding protein alpha (C/EBPalpha) and C/EBPalpha myeloid oncoproteins induce bcl-2 via interaction of their basic regions with nuclear factor-kappaB p50.
Mol Cancer Res
; 3(10): 585-96, 2005 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-16254192
20.
Improved Behavior and Neuropsychological Function in Children With ROHHAD After High-Dose Cyclophosphamide.
Pediatrics
; 138(1)2016 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-27313069